

# Georg StÃ¼ssli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3193456/publications.pdf>

Version: 2024-02-01

82  
papers

2,281  
citations

279798

23  
h-index

223800

46  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4111  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.  | 1.8 | 5         |
| 2  | Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2024-2026.  | 2.4 | 0         |
| 3  | Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296.  | 3.7 | 4         |
| 4  | Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. <i>Blood Advances</i> , 2021, 5, 4674-4685.  | 5.2 | 10        |
| 5  | A qualitative exploration of interactional and organizational determinants of collaboration in cancer palliative care settings: Family membersâ€™, health care professionalsâ€™ and key informantsâ€™ perspectives. <i>PLoS ONE</i> , 2021, 16, e0256965.                                      | 2.5 | 4         |
| 6  | Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.  | 1.4 | 3         |
| 7  | Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. <i>Blood Advances</i> , 2020, 4, 3699-3707.   | 5.2 | 17        |
| 8  | Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 833-836.  | 2.1 | 15        |
| 9  | Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.  | 5.2 | 12        |
| 10 | Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.  | 5.2 | 14        |
| 11 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.   | 1.4 | 86        |
| 12 | Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS. <i>Hematological Oncology</i> , 2020, 38, 197-200.  | 1.7 | 2         |
| 13 | Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1751-1759.   | 7.2 | 18        |
| 14 | Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , 2020, 105, 2584-2591.   | 3.5 | 27        |
| 15 | Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9562.   | 2.6 | 3         |
| 16 | Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 173-174. | 3.0 | 17        |
| 17 | Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. <i>Hematological Oncology</i> , 2019, 37, 595-600.   | 1.7 | 28        |
| 18 | International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278.  | 0.4 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. <i>Cancer Epidemiology</i> , 2019, 59, 51-57.   | 1.9 | 14        |
| 20 | The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019, 104, 1633-1639.  | 3.5 | 28        |
| 21 | Red Blood Cells: Exchange, Transfuse, or Deplete. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 407-416.   | 1.6 | 25        |
| 22 | Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1029-1037.  | 2.4 | 18        |
| 23 | The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. <i>Haematologica</i> , 2019, 104, 710-716. | 3.5 | 29        |
| 24 | Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. <i>Journal of Immunological Methods</i> , 2019, 475, 112348.   | 1.4 | 26        |
| 25 | Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569.   | 1.4 | 3         |
| 26 | I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 4752-4752.   | 1.4 | 0         |
| 27 | Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018, 103, e245-e248.   | 3.5 | 29        |
| 28 | Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.   | 1.4 | 223       |
| 29 | PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.   | 7.0 | 92        |
| 30 | Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. <i>Cancer Epidemiology</i> , 2018, 52, 55-62.   | 1.9 | 8         |
| 31 | Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.  | 1.4 | 7         |
| 32 | Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. <i>Swiss Medical Weekly</i> , 2018, 148, w14589.           | 1.6 | 2         |
| 33 | Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2551-2551.  | 1.4 | 1         |
| 34 | Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research). <i>Blood</i> , 2018, 132, 2875-2875.  | 1.4 | 0         |
| 35 | Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. <i>Cancer Epidemiology</i> , 2017, 46, 85-92.   | 1.9 | 27        |
| 36 | Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1548-1560.  | 1.3 | 23        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Effects of the Sympathomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108. | 1.4  | 4         |
| 38 | Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. <i>Blood</i> , 2016, 128, 4187-4187.   | 1.4  | 6         |
| 39 | Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4367-4367.   | 1.4  | 0         |
| 40 | Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012. <i>Blood</i> , 2016, 128, 5539-5539.   | 1.4  | 0         |
| 41 | Bone Marrow Involvement in Unknown Acute Myeloid Leukemia Detected by 18F-FDG PET/MRI. <i>Clinical Nuclear Medicine</i> , 2015, 40, e486-e487.  | 1.3  | 4         |
| 42 | The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.  | 7.0  | 237       |
| 43 | The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. <i>Blood</i> , 2015, 126, 4005-4005.   | 1.4  | 1         |
| 44 | Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). <i>Leukemia and Lymphoma</i> , 2014, 55, 87-91.   | 1.3  | 23        |
| 45 | Unusual Case of Progressive Multifocal Leukoencephalopathy After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, e33-e34.   | 1.6  | 6         |
| 46 | Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. <i>Lancet, The</i> , 2014, 383, 436-448.   | 13.7 | 322       |
| 47 | The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , 2014, 124, 1782-1782.                                    | 1.4  | 1         |
| 48 | The changing paradigm of chronic lymphocytic leukemia management. <i>European Journal of Internal Medicine</i> , 2013, 24, 401-410.   | 2.2  | 7         |
| 49 | Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation. <i>Frontiers in Immunology</i> , 2013, 4, 125.   | 4.8  | 32        |
| 50 | Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 465-473.  | 2.5  | 46        |
| 51 | Extranodal <sc>NK</sc>/<sc>T</sc>â€œcell lymphoma with leukaemic presentation. <i>British Journal of Haematology</i> , 2013, 161, 754-754.  | 2.5  | 3         |
| 52 | Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. <i>Swiss Medical Weekly</i> , 2013, 143, w13757.  | 1.6  | 4         |
| 53 | Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2122-2129.  | 0.7  | 41        |
| 54 | ABO-incompatible kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 376-85.  | 1.6  | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. <i>Haematologica</i> , 2012, 97, 116-122. | 3.5 | 81        |
| 56 | Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 608-616.                | 2.0 | 43        |
| 57 | Optimised radiological diagnosis of hepatic fungal infection during the treatment of leukemia. <i>Mycoses</i> , 2012, 55, 447-453.   | 4.0 | 0         |
| 58 | Castleman's disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level?. <i>Vasa - European Journal of Vascular Medicine</i> , 2012, 41, 145-148.  | 1.4 | 3         |
| 59 | Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. <i>Blood</i> , 2012, 120, 3906-3906.   | 1.4 | 2         |
| 60 | Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2011, 96, 119-127.  | 3.5 | 14        |
| 61 | Erythroleukaemia at second glance. <i>European Journal of Haematology</i> , 2011, 86, 358-359.   | 2.2 | 0         |
| 62 | Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. <i>Annals of Hematology</i> , 2011, 90, 89-94.                            | 1.8 | 15        |
| 63 | Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. <i>Swiss Medical Weekly</i> , 2011, 141, w13203.                          | 1.6 | 8         |
| 64 | Transfusion of Cryopreserved Autologous Platelets to Overcome HLA Alloimmunization in Patients with Hematological Malignancies. <i>Blood</i> , 2011, 118, 3375-3375.   | 1.4 | 0         |
| 65 | Allogeneic Transplantation for Multiple Myeloma – the Swiss Experience. <i>Blood</i> , 2011, 118, 3112-3112.   | 1.4 | 0         |
| 66 | Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 664-665.   | 2.5 | 4         |
| 67 | Erythroblastic islands. <i>British Journal of Haematology</i> , 2010, 150, 499-499.  | 2.5 | 1         |
| 68 | 5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07). <i>Blood</i> , 2010, 116, 2181-2181.  | 1.4 | 0         |
| 69 | Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. <i>European Journal of Haematology</i> , 2009, 82, 194-200.   | 2.2 | 27        |
| 70 | Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with <i>RUNX1</i> rearrangement. <i>British Journal of Haematology</i> , 2009, 146, 346-346.  | 2.5 | 1         |
| 71 | Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. <i>Haematologica</i> , 2009, 94, 239-248.            | 3.5 | 73        |
| 72 | Reactivity of Human Natural Antibodies to Endothelial Cells From Gal(1,3)Gal-Deficient Pigs. <i>Transplantation</i> , 2007, 83, 193-201.   | 1.0 | 68        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Flow Cytometric Measurement of ABO Antibodies in ABO-Incompatible Living Donor Kidney Transplantation. <i>Transplantation</i> , 2007, 84, S20-S23.  | 1.0 | 24        |
| 74 | ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. <i>Swiss Medical Weekly</i> , 2007, 137, 13-20.  | 1.6 | 5         |
| 75 | ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. <i>Transfusion and Apheresis Science</i> , 2006, 35, 59-69.   | 1.0 | 34        |
| 76 | Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.. <i>Xenotransplantation</i> , 2006, 13, 126-132.   | 2.8 | 13        |
| 77 | High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.. <i>Blood</i> , 2006, 108, 5352-5352. | 1.4 | 0         |
| 78 | ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 1006-1013.  | 2.0 | 124       |
| 79 | Continuous Complete Molecular Remission after Withdrawal of Imatinib Mesylate in Relapsed CML after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 4686-4686.   | 1.4 | 0         |
| 80 | Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. <i>British Journal of Haematology</i> , 2001, 113, 251-253.   | 2.5 | 42        |
| 81 | HLA-G Inhibits Rolling Adhesion of Activated Human NK Cells on Porcine Endothelial Cells. <i>Journal of Immunology</i> , 2001, 167, 6002-6008.  | 0.8 | 74        |
| 82 | Acral Necrosis of the Fingers as Initial Manifestation of Cutaneous Polyarteritis Nodosa. <i>Angiology</i> , 2001, 52, 63-67.   | 1.8 | 16        |